{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:27:50Z","timestamp":1787243270369,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.urolonc.2022.10.014","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:59:34Z","timestamp":1668067174000},"page":"105.e1-105.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden"],"prefix":"10.1016","volume":"41","author":[{"given":"Christopher D.","family":"Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen E.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.10.014_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41585-019-0258-3","article-title":"Financial toxicity associated with treatment of localized prostate cancer","volume":"17","author":"Imber","year":"2020","journal-title":"Nature Rev Urol"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0002","unstructured":"Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ\u00ae)\u2013Patient Version - National Cancer Institute. Published 2017. Accessed March 4, 2021. https:\/\/www.cancer.gov\/about-cancer\/managing-care\/track-care-costs\/financial-toxicity-pdq"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.014_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11764-018-0723-7","article-title":"Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors","volume":"13","author":"Pearce","year":"2019","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0004","article-title":"Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions","volume":"20","author":"Desai","year":"2020","journal-title":"EClin Med"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0005","unstructured":"Board of Governors of the Federal Reserve. Economic Well-Being of U.S. Households in 2020. Federal Reserve. Published 2020. https:\/\/www.federalreserve.gov\/publications\/2021-economic-well-being-of-us-households-in-2020-dealing-with-unexpected-expenses.htm#:\u223c:text =As%20with%20the%20financial%20setbacks,amount%20between% 20%241%2C000%20and%20%241%2C999. Accessed October 15, 2021."},{"issue":"12","key":"10.1016\/j.urolonc.2022.10.014_bib0006","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.urolonc.2021.08.026","article-title":"Out-of-pocket costs for commercially insured patients with localized prostate cancer","volume":"39","author":"Wallis","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2021.02.007","article-title":"Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action","author":"Bhanvadia","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.10.014_bib0008","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0010","unstructured":"Cancer Statistics Review, 1975-2013 - Previous Version - SEER Cancer Statistics Review. SEER. Accessed March 4, 2021. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/index.html"},{"issue":"7","key":"10.1016\/j.urolonc.2022.10.014_bib0011","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.10.014_bib0012","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/JU.0000000000001423","article-title":"Patient-Reported financial toxicity associated with contemporary treatment for localized prostate cancer","volume":"205","author":"Stone Benjamin","year":"2021","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.10.014_bib0013","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.31913","article-title":"Medical financial hardship among cancer survivors in the United States","volume":"125","author":"Zheng","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.09.030","article-title":"A national cross-sectional survey of financial toxicity among bladder cancer patients","volume":"39","author":"Ehlers","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.10.014_bib0015","unstructured":"Medical Expenditure Panel Survey (MEPS): Experiences with cancer survivorship supplement. Accessed August 23, 2020. https:\/\/healthcaredelivery.cancer.gov\/meps\/"},{"issue":"7","key":"10.1016\/j.urolonc.2022.10.014_bib0016","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1055-9965.EPI-18-1336","article-title":"Financial hardship and quality of life among African American and white cancer survivors: the role of limiting care due to cost","volume":"28","author":"Hastert","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"10.1016\/j.urolonc.2022.10.014_bib0017","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cncr.33613","article-title":"Material, behavioral, and psychological financial hardship among survivors of childhood cancer in the Childhood Cancer Survivor Study","volume":"127","author":"Fair","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.014_bib0018","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.surg.2019.09.010","article-title":"Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors","volume":"167","author":"Barrows","year":"2020","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.014_bib0019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2014.001542","article-title":"Population-Based assessment of cancer survivors\u2019 financial burden and quality of life: a prospective cohort study","volume":"11","author":"Zafar","year":"2015","journal-title":"J Oncol Pract"},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.014_bib0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JOP.2013.001322","article-title":"Impact of financial burden of cancer on survivors\u2019 quality of life","volume":"10","author":"Fenn","year":"2014","journal-title":"JOP"},{"issue":"8","key":"10.1016\/j.urolonc.2022.10.014_bib0021","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1200\/JOP.18.00618","article-title":"Conversations about financial issues in routine oncology practices: a multicenter study","volume":"15","author":"Warsame","year":"2019","journal-title":"JOP"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.014_bib0022","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1200\/jco.2013.31.15_suppl.6512","article-title":"Determining value of high cost cancer therapies and discussing cost of cancer care: the patient perspective","volume":"31","author":"Rajguru","year":"2013","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.urolonc.2022.10.014_bib0023","first-page":"5709","article-title":"Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity","volume":"28","author":"Fischer","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.014_bib0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.aje.a115129","article-title":"Agreement between questionaire data and medical records: the evidence for accuracy of recall","volume":"129","author":"Harlow","year":"1989","journal-title":"Am J Epidemiol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:32Z","timestamp":1761042332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1078143922003957"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}